@FierceBiotech: Startup Bina Technologies tries Apple-like strategy in genomics field. Item | Follow @FierceBiotech
@JohnCFierce: Big week for Pfizer coming up, with tofacitinib panel. They need a win here to regain some R&D cred. Article | Follow @JohnCFierce
@RyanMFierce: Fumapharm AG shareholders take early payday on BG-12 interest in $761M Royalty Pharma deal. Release | Follow @RyanMFierce
@MarkHFierce: Scientists have identified a gene linked to a rare condition where babies are born minus a spleen. Release | Follow @MarkHFierce
> A study found that HIV patients were healthy 10 years after getting gene therapy, quelling concerns about risk of developing leukemia from the DNA treatment. Article
> Eli Lilly ($LLY) and Genentech are two big players interested in brown fat targets for treating obesity, yet startups such as Ember Therapeutics and Energesis have some hot leads on ways to harness good fat to fight bad fat. Story
> Pfizer ($PFE) failed in two separate clinical trials of the drug giant's painkiller Lyrica for treating nerve pain in HIV and diabetes patients. Report
Pharma News
@FiercePharma: Derek Lowe's take on the GSK-won't-buy-AstraZeneca story. Hint: Fig Newtons figure in. More | Follow @FiercePharma
@EricPFierce: FDA says drugs shortages are down dramatically. Commissioner gives president credit. Really? Report | Follow @EricPFierce
> Feds nab suspects in $70M Lilly heist. News
> Drug shortages have fallen dramatically, FDA says. Article
> Pfizer, Lilly, AstraZeneca giving NIH abandoned drugs. Story
> GSK's Witty has no interest in buying AstraZeneca. More
Medical Devices News
@FierceMedDev: CBS News: Eye implants restore vision in two British patients--with photo. News | Follow @FierceMedDev
> Qiagen snatches up maker of amniotic fluid detection test. News
> Retinal implants yield amazing results in U.K., China. More
> (Lack of) FDA device monitoring draws new scrutiny. Article
> U.K. regulators toughen focus against counterfeit devices and drugs. Story
And Finally… Forbes contributor Avik Roy makes a case for early approvals of drugs that show promise in mid-stage studies, extending FDA rules for accelerated approvals of meds against life-threatening disease to those for chronic conditions such as diabetes and heart disease. Item